Maintaining CDK4/6 inhibition constrains drug‑resistant breast tumors by delaying cell‑cycle entry, and adding CDK2 inhibition further deepens control to guide post‑progression therapy.
An ad hoc multidisciplinary committee explored what is known about effective science communication and described a comprehensive research agenda to improve the communication of science to inform ...
(Updated - June 18, 2025 12:30 PM EDT) Caris Life Sciences (CAI) debuted on NYSE at $27 on Wednesday, after pricing its IPO at... Today’s IPO for Caris Life Sciences (CAI) is indicated to open at $30 ...
People have been obsessed with cheating death for millennia, but until recently, little had been understood about how to extend life—or if it was even possible. Scientists now say they are getting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback